{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:50:41Z","timestamp":1772164241310,"version":"3.50.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Accumulation of distinct sets of genetic\/epigenetic alterations is thought to contribute to stepwise progression of human cutaneous melanomas. We found evidence of frequent tumor cell autonomous transforming growth factor-\u03b2 (TGF-\u03b2) signal activation in both premalignant and malignant stages of human cutaneous melanoma histogenesis and investigated its potential causative roles using human organotypic skin cultures. PTEN deficiency and Braf activation, two common coincident genetic alterations found in primary cutaneous melanomas, were first introduced into human melanocytes previously immortalized by the SV40 large T antigen and telomerase. These changes individually supported anchorage-independent growth and conferred benign, hyperplastic growth in a skin-like environment. In addition, PTEN deficiency combined with Braf activation together induced a melanoma in situ\u2013like phenotype without dermal invasion. Further addition of cell autonomous TGF-\u03b2 activation in the context of PTEN deficiency and Braf activation promoted dermal invasion in skin cultures without significantly promoting proliferation in vitro and in vivo. This proinvasive phenotype of cell autonomous TGF-\u03b2 activation is genetic context\u2013dependent, as hyperactivating the TGF-\u03b2 type I receptor without PTEN deficiency and Braf activation failed to induce an invasive behavior. Evidence of genetic interactions among PTEN deficiency, Braf activation, and cell autonomous TGF-\u03b2 activation shows that distinct stages of human melanoma are genetically tractable in the proper tissue architecture. [Cancer Res 2008;68(11):4248\u201357]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5671","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T13:50:30Z","timestamp":1212414630000},"page":"4248-4257","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Transforming Growth Factor-\u03b2 Activation Promotes Genetic Context\u2013Dependent Invasion of Immortalized Melanocytes"],"prefix":"10.1158","volume":"68","author":[{"given":"Roger S.","family":"Lo","sequence":"first","affiliation":[{"name":"1Division of Dermatology\/Department of Medicine,"},{"name":"4David Geffen School of Medicine, and"},{"name":"5Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at University of California at Los Angeles and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen N.","family":"Witte","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Immunology and Molecular Genetics,"},{"name":"3Department of Molecular and Medical Pharmacology,"},{"name":"4David Geffen School of Medicine, and"},{"name":"5Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at University of California at Los Angeles and"},{"name":"6Howard Hughes Medical Institute, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,6,2]]},"reference":[{"key":"2022061700403166000_B1","doi-asserted-by":"crossref","unstructured":"Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med\u20082004; 351: 998\u20131012.","DOI":"10.1056\/NEJMra041245"},{"key":"2022061700403166000_B2","doi-asserted-by":"crossref","unstructured":"Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer\u20082003; 3: 559\u201370.","DOI":"10.1038\/nrc1145"},{"key":"2022061700403166000_B3","doi-asserted-by":"crossref","unstructured":"Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med\u20082006; 355: 51\u201365.","DOI":"10.1056\/NEJMra052166"},{"key":"2022061700403166000_B4","doi-asserted-by":"crossref","unstructured":"Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol\u20082006; 24: 4340\u20136.","DOI":"10.1200\/JCO.2006.06.2984"},{"key":"2022061700403166000_B5","doi-asserted-by":"crossref","unstructured":"Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med\u20082005; 353: 2135\u201347.","DOI":"10.1056\/NEJMoa050092"},{"key":"2022061700403166000_B6","doi-asserted-by":"crossref","unstructured":"Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science\u20082006; 313: 521\u20132.","DOI":"10.1126\/science.1127515"},{"key":"2022061700403166000_B7","doi-asserted-by":"crossref","unstructured":"Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med\u20082006; 12: 925\u201332.","DOI":"10.1038\/nm1448"},{"key":"2022061700403166000_B8","doi-asserted-by":"crossref","unstructured":"Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem\u20082007; 101: 862\u201372.","DOI":"10.1002\/jcb.21204"},{"key":"2022061700403166000_B9","doi-asserted-by":"crossref","unstructured":"Khavari PA. Modelling cancer in human skin tissue. Nat Rev Cancer\u20082006; 6: 270\u201380.","DOI":"10.1038\/nrc1838"},{"key":"2022061700403166000_B10","doi-asserted-by":"crossref","unstructured":"Hoek KS, Schlegel NC, Brafford P, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res\u20082006; 19: 290\u2013302.","DOI":"10.1111\/j.1600-0749.2006.00322.x"},{"key":"2022061700403166000_B11","doi-asserted-by":"crossref","unstructured":"Bruna A, Darken RS, Rojo F, et al. High TGF\u03b2-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell\u20082007; 11: 147\u201360.","DOI":"10.1016\/j.ccr.2006.11.023"},{"key":"2022061700403166000_B12","doi-asserted-by":"crossref","unstructured":"Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A\u20082005; 102: 13909\u201314.","DOI":"10.1073\/pnas.0506517102"},{"key":"2022061700403166000_B13","doi-asserted-by":"crossref","unstructured":"Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet\u20082005; 37: 1047\u201354.","DOI":"10.1038\/ng1634"},{"key":"2022061700403166000_B14","unstructured":"Otsuka T, Takayama H, Sharp R, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res\u20081998; 58: 5157\u201367."},{"key":"2022061700403166000_B15","unstructured":"Yu Y, Merlino G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res\u20082002; 62: 2951\u20136."},{"key":"2022061700403166000_B16","doi-asserted-by":"crossref","unstructured":"Fang D, Leishear K, Nguyen TK, et al. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells\u20082006; 24: 1668\u201377.","DOI":"10.1634\/stemcells.2005-0414"},{"key":"2022061700403166000_B17","doi-asserted-by":"crossref","unstructured":"Fukunaga-Kalabis M, Martinez G, Liu ZJ, et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol\u20082006; 175: 563\u20139.","DOI":"10.1083\/jcb.200602132"},{"key":"2022061700403166000_B18","doi-asserted-by":"crossref","unstructured":"Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene\u20082003; 22: 3162\u201371.","DOI":"10.1038\/sj.onc.1206455"},{"key":"2022061700403166000_B19","doi-asserted-by":"crossref","unstructured":"Moretti S, Pinzi C, Berti E, et al. In situ expression of transforming growth factor \u03b2 is associated with melanoma progression and correlates with Ki67, HLA-DR and \u03b23 integrin expression. Melanoma Res\u20081997; 7: 313\u201321.","DOI":"10.1097\/00008390-199708000-00006"},{"key":"2022061700403166000_B20","unstructured":"Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-\u03b22 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol\u20081994; 145: 97\u2013104."},{"key":"2022061700403166000_B21","doi-asserted-by":"crossref","unstructured":"Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factor-\u03b2s (TGF-\u03b21, TGF-\u03b22, TGF-\u03b23), and TGF-\u03b2 type II receptor expression in malignant melanoma. Carcinogenesis\u20081995; 16: 1499\u2013503.","DOI":"10.1093\/carcin\/16.7.1499"},{"key":"2022061700403166000_B22","unstructured":"Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-\u03b2 isoforms. Am J Pathol\u20081996; 148: 1887\u201394."},{"key":"2022061700403166000_B23","doi-asserted-by":"crossref","unstructured":"Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor \u03b2 signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A\u20082003; 100: 8430\u20135.","DOI":"10.1073\/pnas.0932636100"},{"key":"2022061700403166000_B24","unstructured":"Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res\u20082003; 63: 8221\u20135."},{"key":"2022061700403166000_B25","doi-asserted-by":"crossref","unstructured":"Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie\u20082005; 87: 307\u201314.","DOI":"10.1016\/j.biochi.2005.01.013"},{"key":"2022061700403166000_B26","doi-asserted-by":"crossref","unstructured":"Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res\u20082005; 11: 5158\u201366.","DOI":"10.1158\/1078-0432.CCR-04-2478"},{"key":"2022061700403166000_B27","doi-asserted-by":"crossref","unstructured":"Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res\u20082006; 16: 207\u201311.","DOI":"10.1097\/01.cmr.0000215033.92693.73"},{"key":"2022061700403166000_B28","doi-asserted-by":"crossref","unstructured":"Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature\u20082007; 445: 851\u20137.","DOI":"10.1038\/nature05661"},{"key":"2022061700403166000_B29","doi-asserted-by":"crossref","unstructured":"Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res\u20082006; 66: 999\u20131006.","DOI":"10.1158\/0008-5472.CAN-05-2720"},{"key":"2022061700403166000_B30","doi-asserted-by":"crossref","unstructured":"Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-\u03b2 in homeostasis and cancer. Nat Rev Cancer\u20082003; 3: 807\u201321.","DOI":"10.1038\/nrc1208"},{"key":"2022061700403166000_B31","doi-asserted-by":"crossref","unstructured":"Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med\u20082000; 342: 69\u201377.","DOI":"10.1056\/NEJM200001133420201"},{"key":"2022061700403166000_B32","doi-asserted-by":"crossref","unstructured":"Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor \u03b2-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res\u20082006; 66: 2202\u20139.","DOI":"10.1158\/0008-5472.CAN-05-3560"},{"key":"2022061700403166000_B33","doi-asserted-by":"crossref","unstructured":"Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res\u20082006; 66: 6546\u201352.","DOI":"10.1158\/0008-5472.CAN-06-0384"},{"key":"2022061700403166000_B34","doi-asserted-by":"crossref","unstructured":"Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma. J Invest Dermatol\u20082004; 122: 337\u201341.","DOI":"10.1046\/j.0022-202X.2004.22243.x"},{"key":"2022061700403166000_B35","doi-asserted-by":"crossref","unstructured":"Singh RS, Diwan AH, Zhang PS, Prieto VG. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. J Cutan Pathol\u20082007; 34: 220\u20135.","DOI":"10.1111\/j.1600-0560.2006.00592.x"},{"key":"2022061700403166000_B36","doi-asserted-by":"crossref","unstructured":"Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res\u20082004; 64: 7002\u201310.","DOI":"10.1158\/0008-5472.CAN-04-1399"},{"key":"2022061700403166000_B37","doi-asserted-by":"crossref","unstructured":"Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet\u20082005; 37: 745\u20139.","DOI":"10.1038\/ng1586"},{"key":"2022061700403166000_B38","doi-asserted-by":"crossref","unstructured":"Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest\u20082007; 117: 719\u201329.","DOI":"10.1172\/JCI30102"},{"key":"2022061700403166000_B39","doi-asserted-by":"crossref","unstructured":"Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell\u20082007; 11: 555\u201369.","DOI":"10.1016\/j.ccr.2007.04.021"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/11\/4248\/2595400\/4248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/11\/4248\/2595400\/4248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:01:49Z","timestamp":1655431309000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/11\/4248\/541041\/Transforming-Growth-Factor-Activation-Promotes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2008,6,2]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5671","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22373754.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373748.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373760","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373745.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373739.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373751","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373742","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373760.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373754","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373757","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373742.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373745","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373748","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373736.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373751.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373757.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6497187","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497187.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}